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itraconazole and terbinafine against clinical isolates ofScedosporium prolijicallS
Results from animal experiments are still scarce and difficult to interpret
because of altered pharmacokinetics in most animals. In humans, synergism
seems to be present for amphotericine combined with flucytosine to treat
infections caused by Cryptococcus spp. It is expected, that new methods to
determine synergism between antifungals will result in a more ratinoal
approach of using combinations of antimycotics in humans.
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The reconstitution of HCMV-specific immune responses after allogeneic
SCT has been demonstrated to be protective against the development of
HCMV disease. S. Riddell and P. Greenberg have shown protective
HCMV-specific T cell immunity to be transfered to the recipients of an
allogeneic stem cell transplant by the infusion of donor-derived ex vivo
generated HCMV-specific cytotoxic T cell (CTL) clones. Alternative
strategies to deplete of alloreactive T cells andlor enrich for CMV specific
T cells in donor PBMNCs are increasingly explored and will be discussed.
One possibility is to pulse dendritic cells, the "professional" antigen
presenting cells, with soluble synthetic peptides to induce and propagate
HCMV specific CTLs from HCMV-seropositive and also HCMV-serone-
gative donors. After repetitive specific stimulation T cell lines highly
enriched for HCMV specific T cells can be generated and safely transferred
to patients. In a phase I/II-study recipients of an allograft with persistent
HCMV infection in spite ofprolonged antiviral chemotherapy received I x
I07/m2 polyclonal cell lines without any significant side effects. A transient
reduction of viral load could be documented in all these patients, the
majority of them showed sucessful control ofHCMV infection.
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Objectives: Genetic modification ofhematopoietic stem cells with anti-HIV
cat:\lytic RNAs (Ribozymes).
Methods: Hammerhead rihozymes targeting the HIV-I tat and rev tran-
scripts are transduced in the backbone of a murine retroviral vector into
primary hetamotpoietic progenitor cells from HIV-I infected individuals.
The ribozymes are expressed as a polycistronic transcript from the LTR of
the LN retroviral vector. Our hypothesis is that stable transduction of
pluripotent hematopoietic stem cells by ribozyme expressing vectors fol-
lowed by engraftment ofthese cells in the marrow, will ultimately provide a
population ofHIV-I resistant T-cells, monocytes, and dendritic cells. To test
this, we have initiated a clinical trial involving HIV-I infected individuals
who have AIDS related lymphoma using vectors harboring ribozyme or
vector backbone alone transduced into their stem cells. In parallel to the
clinical studies, we are testing new strategies for ribozyme-target co-
localization using chimeric RNA molecules, which harbor our rihozymes
of interest tethered to sequences, which direct the ribozymes to discrete
intracellular localizations.
Results: The clinical trial studies have demonstrated a selective survival of
ribozyme expressing cells within a period of several weeks following bone
marrow transplantation and long term engraftment in at least one patient.
Our new chimeric ribozyme localization studies demonstrate that a nucleo-
lar-localized ribozyme is a potent inhibitor of HIV-I.
Condusions: Ribozyme mediated gene therapy for the treatment ofHIV-I
infection is feasible utilizing hematopoietic stem cells. Potent inhibition of
HIV-I infection by a nucleolar ribozyme suggests nucleolar trafficking of
HIV-I RNAs, opening new targets for anti-HIV-I therapies.
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Chronic viral hepatitis due to hepatitis B virus (HBV) or hepatitis C virus
(HCV) infection is a major cause of morbidity and mortality, effecting
hundreds of millions ofindividuals worldwide. Long term complications of
untreated chronic viral hepatitis include progressive liver disease and
hepatocellular carcinoma. Interferon alpha has historically been the first
line treatment for chronic viral hepatitis. However, this therapy is only
moderately effective and is often limited by side effects. Newer agents
including nucleoside analogs for chronic hepatitis B. and ribavirin in
combination with interferon for chronic hepatitis C, have shown promise
for improving response rates. In chronic hepatitis B, antigen tests (HBeAg,
HBsAg), antibody tests (anti-HBs, anti-HBe) and nucleic acid tests (HBV
DNA) are used to monitor response to antiviral therapy, while in chronic
hepatitis C, treatment response is monitored by following qualitative andlor
quantitative HCV RNA in serum. In general, successful treatment of
chronic hepatitis B results in disappearance of the viral antigens and HBV
DNA, and seroconversion to positivc anti-HBs and anti-HBe status. In
chronic hepatitis C, successful treatment is associated with clearance ofHCV
RNA from serum during the first 3-6 months of therapy, and absence of
detectable viral RNA in serum 6 months after cessation of therapy. In both
cases, such responses predict sustained clinical remissions and histological
improvement of liver disease. Drug resistance to nucleoside analog mono-
therapy is well documented in chronic hepatitis B, and appears to result from
critical mutations within the HBV polymerase gene. The role of viral
mutations in detcrmining sensitivity or resistance of HBV and HCV to
interferon therapy is less well defined, primarily due to a lack of suitable
culture systems for phenotypic characterization of putative resistant viral
populations.
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Monitoring of response to treatment by quantitative determination of
antigenemia viremia and leukoDNAemia is the most useful tool for early
detection ofdrug-resistant HCMV strains in immunocompromised patients.
In fact, lack ofreduction or increase in level of measured viral parameters in
blood during therapy suggests the unrestricted viral replication. In parti-
cular. while antigenemia and leukoDNAemia quantitate viral components,
viremia is a direct measure of the amount ofinfectious virus and of the virus
replicative potential during treatment. However, delayed reduction in viral
load during treatment is not invariably associated with the emergence of a
drug-resistant HCMV strain. Thus, rapid confirmatory assays are needed in
order to decide treatment change. A simplified immediate- early plaque-
reduction assay using blood leukocytes as inoculum, allows a rapid (4-6
days) screening for drug-resistance. Detection of specific mutations in
HCMV UL97 or UL54 genes directly in clinical specimens by PCR-based
methods or sequencing allows demonstration of the presence of drug-
resistant strains within 2-3 days. In AIDS patients, disseminated HCMV
infections have been treated mostly in the presence of specific symptoms,
whereas in solid organs or bone marrow recipients adoption of preemptive
therapy protocols implies initiation ofanti-HCMV treatment when patients
are still in the asymptomatic phase of the infection. This difference along
with the need in the recent past of prolonged anti-HCMV maintenance
treatment in AIDS patients might account for the reported greater pre-
valence of HCMV drug-resistant strains in this patient population with
respect to transplant recipients. However. the recent introduction of potent
antiretroviral combination protocols was followed by a drastic reduction in
the prevalence ofHCMV infections in AIDS patients, with a further reduced
number of reported new resistant HCMV strains. In the transplantation
settings, several anedoctical reports ofHCMV drug-resistant strains points to
a possible emerging problem in the near future.
